Eupraxia Pharmaceuticals, Inc. (EPRX)
7.50
+0.05
(+0.67%)
USD |
NASDAQ |
Sep 03, 16:00
7.50
0.00 (0.00%)
After-Hours: 19:09
Eupraxia Pharmaceuticals Debt to Equity Ratio : 0.014 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.014 |
| March 31, 2026 | 0.0146 |
| December 31, 2025 | 0.0019 |
| September 30, 2025 | 0.0019 |
| June 30, 2025 | 0.0016 |
| March 31, 2025 | 0.0018 |
| December 31, 2024 | 0.0022 |
| September 30, 2024 | 0.0098 |
| June 30, 2024 | 0.3142 |
| March 31, 2024 | 0.489 |
| September 30, 2023 | 0.9044 |
| June 30, 2023 | 1.497 |
| Date | Value |
|---|---|
| March 31, 2023 | 1.253 |
| December 31, 2022 | 0.8203 |
| September 30, 2022 | 0.5066 |
| June 30, 2022 | 0.4057 |
| March 31, 2022 | 0.5675 |
| December 31, 2021 | 0.4687 |
| September 30, 2021 | 0.3973 |
| June 30, 2021 | 0.314 |
| March 31, 2021 | 0.2471 |
| December 31, 2020 | -0.8249 |
| September 30, 2020 | -0.7658 |
| December 31, 2019 | -0.9059 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Edesa Biotech, Inc. | 0.00 |
| ProMIS Neurosciences, Inc. | 0.00 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 139.91M |
| Total Liabilities (Quarterly) | 10.23M |
| Shareholders Equity (Quarterly) | 131.28M |
| Current Ratio | 16.00 |
| Net Debt Paydown Yield | -0.08% |